Novartis signs deal to boost cell therapy portfolio
ZURICH, Sept 6
ZURICH, Sept 6 (Reuters) - Swiss drugmaker Novartis AG said on Friday it had signed a licensing and research deal that could boost its ability to develop innovative cell-based therapies for conditions where little treatment is currently available.
The maker of blockbuster blood pressure drug Diovan said it would use a stem-cell based platform developed by U.S.-based biopharmaceutical company Regenerex to help broaden its cell therapy portfolio.
Timothy Wright, head of development at Novartis Pharmaceuticals, said the agreement would support Novartis' leadership position in cell therapy.
- Obama and Castro shake hands, Zuma humiliated at Mandela memorial |
- Google bus blocked in San Francisco gentrification protest
- Thai PM urges protesters to take part in election |
- Reporter allowed to keep sources secret in Colorado theater shooting
- U.S. regulators seek to curb Wall St. trades with Volcker rule